Laser Ablation Treatment of Recurrent Lymph Node Metastases from Papillary Thyroid Carcinoma.
laser ablation
lymph nodes metastases
papillary thyroid carcinoma
recurrence
thyroid carcinoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Nov 2021
14 Nov 2021
Historique:
received:
25
10
2021
revised:
08
11
2021
accepted:
12
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
(1) Background: The incidence of papillary thyroid cancers is increasing. Papillary neoplasm metastasizes to the central and lateral lymph nodes of the neck. The recurrence rate is less than 30%. The gold standard of treatment for lymph node recurrences is surgery, but surgery is burdened by a high rate of complications. Therefore, laser ablation of recurrent lymph nodes has been recognized as an alternative treatment with minimal invasiveness, a low complication rate and a curative effect. (2) Methods: We analyzed 10 patients who underwent a total thyroidectomy and metabolic radiotherapy and who developed a lymph node recurrence in the laterocervical compartment in the following 12-18 months. (3) Results: Patients developed lymph node recurrence at IV and Vb levels in 70% and 30% of cases, respectively. All patients were treated with a single laser ablative session. Hydrodissection was performed in all patients. The energy delivered was 1120 ± 159.3 Joules and 3-4 Watts in 362 ± 45.7 s. No complications were reported. All patients underwent a 6-month follow-up. A volumetric reduction of 40.12 ± 2.2%, 49.1 ± 2.13% and 59.8 ± 3.05%, respectively at 1-, 3- and 6-months of follow-up was reported. (4) Conclusions: At 6 months, a fine needle aspiration was performed, which was negative for malignant cells and negative for a dosage of Thyroglobulin in eluate. The laser ablation is an effective alternative to surgical treatment.
Identifiants
pubmed: 34830577
pii: jcm10225295
doi: 10.3390/jcm10225295
pmc: PMC8618398
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Elesta Spa
ID : 18/21 - DA
Références
Surg Clin North Am. 1992 Jun;72(3):531-58
pubmed: 1589829
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
J Funct Biomater. 2017 Jun 14;8(2):
pubmed: 28613248
Science. 1961 Nov 10;134(3489):1525-6
pubmed: 14009883
J Clin Endocrinol Metab. 2013 Jan;98(1):E92-7
pubmed: 23150695
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):512-8
pubmed: 25928119
Curr Opin Oncol. 2013 Jan;25(1):14-9
pubmed: 23079931
Surgery. 2001 Dec;130(6):971-7
pubmed: 11742325
Photochem Photobiol. 1991 Jun;53(6):825-35
pubmed: 1886941
Nature. 1964 Jul 25;203:417
pubmed: 14197393
Cancer. 2017 Feb 1;123(3):372-381
pubmed: 27741354
Int J Hyperthermia. 2015 Jun;31(4):403-8
pubmed: 25792224
Cardiovasc Intervent Radiol. 2016 Jul;39(7):1023-30
pubmed: 26911732
Crit Rev Biomed Eng. 2010;38(1):79-100
pubmed: 21175405
Radiology. 2011 Feb;258(2):351-69
pubmed: 21273519
J Cancer Res Ther. 2014 Nov;10 Suppl:C144-9
pubmed: 25450273
Radiology. 2015 Sep;276(3):909-18
pubmed: 25848897
Int J Hyperthermia. 2019;36(1):897-904
pubmed: 31464140
World J Surg. 2007 May;31(5):905-15
pubmed: 17219265
Radiology. 1985 Jun;155(3):607-10
pubmed: 3889999
World J Surg. 1983 Nov;7(6):700-9
pubmed: 6419477